Pregunta o busca lo que quieras...
Investigación destacada hoy
Artículos de todas las revistas, en un solo lugar. Crea feeds personalizados.
3w ago
Comentario expertoRevista destacadaDestacado en Circulation
Level 2: RCT
Pulsed Field Ablation Versus Sham to Treat Atrial Fibrillation: The PFA-SHAM Randomized Clinical Trial
Pulsed field ablation cuts 6-month atrial tachyarrhythmia recurrence by ~92% versus sham.
Implicación
PFA markedly outperforms sham for AF recurrence and QoL; confirms ablation benefit beyond placebo in symptomatic patients.
“It provides strong evidence of efficacy of the active treatment and evidence against it just being a placebo effect. And it treats both the doctor and the patient. It treats us by reducing the detected amount of atrial fibrillation that we see with, importantly, a loop recorder in all of these patients. And also it treats the patient because there was subjective improvement in the AFEQT score and the HADS score.”
— Daniel MorinVer fuente
Circulation
Charles University
2w ago
Comentario expertoRevista destacadaDestacado en Circulation
Level 1: Clinical Guideline
Role of Physical Activity in Obesity Treatment and Cardiometabolic Health: A Scientific Statement From the American Heart Association
Implicación
Prescribe physical activity for cardiometabolic gains irrespective of weight loss; extends evidence for multimodal obesity management.
Circulation
1w ago
Comentario expertoDestacado en podcastRevista destacadaDestacado en Circulation
Level 1: Clinical Guideline
Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology
Implicación
Scientific statement examines risk assessment for improving cardiovascular disease prevention strategies.
Circulation
5w ago
Tendencia en XComentario expertoRevista destacadaDestacado en Circulation
Level 2: RCT
Angiotensin Receptor Neprilysin Inhibitor in Heart Failure with Preserved Ejection Fraction and Secondary Mitral Regurgitation: the PRAISE-MR Randomized Trial
Sacubitril/valsartan improves exercise mPAP/CO slope by ~0.93 mmHg/L/min versus SOC in HFpEF with AFMR.
Implicación
Supports sacubitril/valsartan over SOC in HF with adverse exercise hemodynamics; extends prior ARNI trials to this invasive endpoint.
“The PRAISE-MR trial is the first prospectively randomized trial to demonstrate that sacubitril/valsartan significantly improves exercise hemodynamics, functional capacity, and quality of life in patients with HFpEF and AFMR. These findings underscore that the phenotypic heterogeneity of HFpEF nec...”
— ACC Journal ScanVer fuente
Circulation
Vrije Universiteit Brussel
3d ago
Revista destacadaDestacado en Circulation
Level 1: Clinical Guideline
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association
Implicación
May enhance CV endpoint consistency in oncology trials; leaves open effects on outcomes or regulatory decisions pending validation.
Circulation
3w ago
Comentario expertoRevista destacadaDestacado en ESC Press Release
Level 1: Clinical Guideline
Women's heart centres: a clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the Heart Failure Association (HFA), and the Association for Acute CardioVascular Care (ACVC) of the ESC
Implicación
Supports women's heart centre implementation to reduce sex-based care gaps; extends consensus on specialized pathways and training.
European Heart Journal
Harvard University
2w agoOpen Access
Comentario expertoRevista destacadaDestacado en Circulation
Level 3: Cohort Study
Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials
Intervention-induced visceral fat loss linked to ~28% lower incident T2D risk per ten percent reduction.
Implicación
Visceral fat loss may inform diabetes prevention targets; hypothesis-generating and requires randomized confirmation.
“Repeated participation in a lifestyle program for weight loss, even after a perceived 'failure,' may lead to significant health benefits over the years, especially in reducing dangerous abdominal fat.”
— Iris ShaiVer fuente
Circulation
Harvard University
2w ago
Comentario expertoRevista destacadaDestacado en ACC Journal Scan
Level 2: RCT
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
Low-dose rivaroxaban fails to reduce cardiovascular events versus placebo in advanced CKD.
Implicación
Does not support low-dose rivaroxaban for cardiovascular prevention in advanced CKD; confirms lack of efficacy with increased major bleeding.
“TRACK sets the direction for the questions that must be asked next, particularly regarding which patients are most likely to benefit (e.g., those with established cardiovascular disease) and whether alternative oral anticoagulation strategies may prove more effective or safer in selected CKD popu...”
— ACC Journal ScanVer fuente
JAMA
University College London
2w ago
Revista destacada
Level 1: Meta-Analysis
Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages
Finerenone reduces CV and kidney events and increases CKM syndrome regression ~66% versus placebo.
Implicación
Supports finerenone across CKM stages in T2D-CKD; extends prior RCTs to include syndrome regression.
“Importantly, participants who experience new-onset AFib/AFL were at a substantially higher subsequent risk of adverse cardiovascular and kidney outcomes than were those who remained free of AFib/AFL during follow-up. These findings highlight the role of finerenone in reducing the risk of new-onset AFib/AFL, mitigating downstream complications, and ultimately improving outcomes in patients across the CKM spectrum.”
— Dr. Maria A. PabonVer fuente
JAMA Cardiology
University of Michigan
2w ago
Revista destacada
Level 2: RCT
Precardioversion Heart Rhythm Monitoring Using Smartphone Photoplethysmography
Precardioversion smartphone photoplethysmography reduces same-day cardioversion cancellations by ~79% versus standard care.
Implicación
Reduces same-day cancellations and resource waste in AF cardioversion; extends smartphone photoplethysmography evidence to preprocedural monitoring.
JAMA Cardiology
Karolinska Institutet
